ClinicalTrials.gg
RecruitingNCT06494072Updated Mar 2, 2026

Short Versus Standard of Care Antibiotic Duration for Children Hospitalized for CAP

A Phase 4 interventional study of Ampicillin for Injection and Ceftriaxone for Injection in Community Acquired Pneumonia in Children, sponsored by Medical College of Wisconsin. Recruiting at 1 site in United States. Open to participants aged 3 Months to 18 Years. Per ClinicalTrials.gov, last updated 2026-03-02.

Sponsored by Medical College of Wisconsin · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Aug 2024; still recruiting 2 years 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
236
Allocation
Randomized
Ages
3 Months to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 52 studies in Community-Acquired Pneumonia with a site in United States — 9 open to participants now, 12 under way, 3 of them phase 3. Community-Acquired Pneumonia · United States.

Planned enrollment
20th of 42
236 · median 190
Started
2024
with 2 others
Phase 4
7 of 52
3 open now
Primary completion
2028-05
later than 5 of 11 live
Registered
45th of 52
by date

Among the 52 studies in Community-Acquired Pneumonia with a site in United States, this one is the 20th largest by planned enrollment of the 42 interventional ones that give a count, is one of 3 that started in 2024, is one of 7 in phase 4, reaches primary completion later than 5 of the 11 other live ones, and was the 45th registered.

Community-Acquired Pneumonia

325 studies on the registry are indexed under Community-Acquired Pneumonia; 77 are open to participants now.

Browse Community-Acquired Pneumonia studies →

Open to participants now

9 of the 52 studies in Community-Acquired Pneumonia with a site in United States are open now. Recruiting first, the newest first:

3 more — sign in →

All 9 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 41 Community-Acquired Pneumonia studies recruiting now, 29 (71%) set no upper age limit and 9 (22%) stop at 75 or younger; 13 take children under 18; 5 take healthy volunteers.

This study: 3 Months to 18 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 52 studies in Community-Acquired Pneumonia with a site in United States, or all of them as a file.
02

Study summary

The goal of this open label, randomized, non-inferiority clinical trial is to compare the treatment success of a 5 day antibiotic course versus a standard antibiotic course (usually 7-14 days of antibiotics) in hospitalized children aged 3 months to 18 years, with uncomplicated community acquired pneumonia.

The main questions it aims to answer are:

  • Does a 5 day course work as well as standard (longer) courses of antibiotics for treating community acquired pneumonia in children?
  • Does a 5 day course cause less antibiotic side effects compared to a standard (longer) course of antibiotics in children with community acquired pneumonia?

Participants will

  • be randomly assigned to either receive 5 total days or a total duration decided by the treating physician
  • receive a brief follow up questionnaire regarding clinical symptoms, follow up care/antibiotics, and side effects via phone or email at days 5 and 14 from the start of antibiotics

Researchers will compare the experimental group (receiving 5 days duration) with the control group (standard duration) to see if 5 days is as successful as a standard duration.

Read the detailed description

This is an open label, randomized, non-inferiority clinical trial to determine if a 5-day antibiotic course works as well compared to a standard antibiotic course (usually 7-10 days of antibiotics) in hospitalized children who are aged 3 months to less than 18 years old, with uncomplicated community acquired pneumonia.

We will recruit 150 participants meeting inclusion/exclusion criteria. Participants will be randomized to one of the study groups. In the experimental group, the participant will receive a total antibiotic course of 5 days. In the other group (control group), participants will receive the standard-of-care antibiotic course (the duration will be decided by the primary treating physician in this group). The selection of antibiotic therapy will be made by the treating physician, generally in accordance with the institutional clinical practice guideline on community acquired pneumonia, prior to enrollment in the study. Other medical care, aside from the treatment duration, will be the same and will be guided by the primary treating doctor. The primary treating doctor will also decide when the participant is medically ready for discharge from the hospital.

During the consenting process, a member of the research team will verify the contact numbers or email of the parent(s)/guardian of participant to be used after discharge for follow-up communication. Every participant's parent/guardian will receive a text message/email questionnaire on day 5 and day 14 after the start of antibiotics to assess for clinical improvement, side effect(s) to the antibiotics, recurrence of fever, or need for additional antibiotics or other medical care. Participants parent(s)/guardian will be contacted by phone for additional information if there is concern for a failure or significant medical concern.

The primary objective of this study is to compare the failure rate between a short course (5-days) and standard antibiotic course (usually 7-10 days of antibiotics) of antibiotics in hospitalized children with uncomplicated pneumonia. Failure will be defined as the clinical need for additional antibiotic treatment, emergency department visit or readmission to the hospital for a suspected lower respiratory tract infection within 14 days of treatment initiation.

The secondary objective will compare the rate of adverse drug events between short and long-course durations of antibiotic therapy in children hospitalized for CAP. Adverse drug events include any allergic reaction such as skin rash, itching or other and/or abdominal symptoms such as vomiting, stomach pain and diarrhea.

Data will be summarized by n (%) or mean and standard deviation (SD) or median and interquartile range (IQR). Continuous variables will be compared by t-test while categorical variables will be compared by Chi-square or Fisher's exact test. A 95% CI will be calculated for the difference in failure rate between the shorter antibiotic course (5-day) group and the standard course group. Non-inferiority will be declared if the 95% CI lies below 10%. P\<0.05 will be considered statistically significant. Data will be analyzed by SAS version 9.4 (SAS Institute Inc., Cary, NC) and SPSS version 28.0 (IBM Corp., Armonk, NY).

03

Conditions studied

  • Community Acquired Pneumonia in Children

Keywords

  • inpatient
  • pediatric
  • hospitalized
  • community acquired pneumonia.
  • antibiotic duration
04

Who can participate

Ages eligible
3 Months to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria (ALL of the following must be met):

  1. Children aged 3 months to \<18 years old
  2. Hospitalized in either the acute care or the pediatric intensive care units
  3. Clinically diagnosed with uncomplicated bacterial community acquired pneumonia (as determined by the treating physician)
  4. Radiological findings suggestive of pneumonia (such as consolidation, lobar or interstitial infiltrates)
  5. Achieved clinical stability within 72 hours from the first antibiotic dose (clinical stability includes being off supplemental oxygen/ventilatory support and temperature remaining \< 38 Celsius).

Exclusion Criteria (presence of ANY of the following will exclude a potential participant):

  1. Hemodynamic instability at any point during hospitalization that required inotropic support
  2. Requirement of respiratory support > 72 hours
  3. Presence of a parapneumonic effusion >10 mm on decubitus x-ray or greater than ¼ of hemithorax opacified on chest imaging
  4. Need for chest tube placement
  5. Extrapulmonary involvement (ie: another infection located outside of the lungs) except for otitis media if the planned treatment is ≤ 5 days
  6. Pneumonia caused by known staphylococcus aureus identified from culture (blood, bronchoalveolar aspirate, tracheal aspirate, or pleural fluid)
  7. Antibiotic course started >72 hours after admission
  8. Antibiotics used for > 24 hours within the 2 weeks prior to admission
  9. Chronic respiratory illness other than asthma or reactive airway disease
  10. patient (primary or secondary)
  11. Primary physician refusal
  12. Parent refusal
  13. Non-English speakers
  14. Pregnant or lactating female
  15. Participant will become ≥ 18 years old at or before the time of day 14 follow up
  16. Inability to adhere to follow up
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
236 participants (estimated)

Study arms

  • Experimental
    Short course antibiotic duration

    The participants in this group will receive a total antibiotic course of 5 days including the number of days received during their hospital admission and following hospital admission combined.

    Drug: Ampicillin for Injection · Drug: Ceftriaxone for Injection · Drug: Amoxicillin · Drug: Ampicillin / Sulbactam Injection · Drug: Amoxicillin-clavulanate · Drug: Clindamycin · Drug: Cefprozil · Drug: Levofloxacin

  • Active comparator
    Standard of care antibiotic duration

    Participants will receive the standard-of-care antibiotic course in this group. That is, the duration of antibiotics will be decided by the primary treating physician in this group. The antibiotic course will include the number of days received during the participant's hospital admission and following hospital admission combined.

    Drug: Ampicillin for Injection · Drug: Ceftriaxone for Injection · Drug: Amoxicillin · Drug: Ampicillin / Sulbactam Injection · Drug: Amoxicillin-clavulanate · Drug: Clindamycin · Drug: Cefprozil · Drug: Levofloxacin

Interventions

  • DrugAmpicillinStudies of AmpicillinAmpicillin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Ampicillin is an intravenous antibiotic commonly used in the initial treatment of children hospitalized with community-acquired pneumonia.

  • DrugCeftriaxoneStudies of CeftriaxoneCeftriaxone pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Ceftriaxone is an intravenous antibiotic commonly used in the initial treatment of children hospitalized with community-acquired pneumonia.

    Also known as: Rocephin

  • Amoxicillin is an oral antibiotic commonly used in the treatment of children hospitalized with community-acquired pneumonia to complete the antibiotic course after discharge.

  • DrugAmpicillin / Sulbactam Injection

    Drug pages: AmpicillinStudies of AmpicillinAmpicillin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · SulbactamStudies of SulbactamSulbactam pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Ampicillin/Sulbactam is an intravenous antibiotic commonly used in the initial treatment of children hospitalized with community-acquired pneumonia.

    Also known as: Unasyn

  • DrugAmoxicillin-clavulanate

    Drug pages: AmoxicillinStudies of AmoxicillinAmoxicillin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · Clavulanic AcidStudies of Clavulanic AcidClavulanic Acid pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Amoxicillin-clavulanate is an oral antibiotic commonly used in the treatment of children hospitalized with community-acquired pneumonia to complete the antibiotic course after discharge.

    Also known as: Augmentin

  • Clindamycin is an antibiotic that can be given intravenously or orally that is sometimes used in the treatment of children hospitalized or discharged with community-acquired pneumonia.

    Also known as: Cleocin

  • Cefprozil is an oral antibiotic sometimes used in the treatment of children hospitalized with community-acquired pneumonia to complete the antibiotic course after discharge.

    Also known as: Cefzil

  • Levofloxacin is an antibiotic that can be given intravenously or orally that is sometimes used in the treatment of children hospitalized or discharged with community-acquired pneumonia.

    Also known as: Levaquin

06

What researchers measure

Primary outcomes

  1. Treatment failure rate

    Treatment failure is defined as the clinical need for additional antibiotic treatment, an emergency department (ED) visit, or readmission to the hospital for a suspected lower respiratory tract infection within 14 days of treatment initiation.

    Time frame: 14 days from the first dose antibiotics

Secondary outcomes

  1. Adverse drug event rate

    Adverse drug events include allergic reactions, skin rash, abdominal symptoms (such as vomiting, stomach pain, or diarrhea), or other plausible associated complaints described by the parent(s)/guardian.

    Time frame: 14 days from the first dose antibiotics

07

Study locations

1 of 1 sites recruiting
  • Childrens Wisconsin
    Milwaukee, Wisconsin 53226, United States
    Recruiting
    • Michelle Mitchell, MD · Contactmimitchell@mcw.edu · 4143377070
    • Michelle Mitchell, MD · Principal investigator
    • khaled al zubaidi, MD · Sub investigator
08

References and documents

Individual participant data

Plan to share: No — Aggregated data results will be provided.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Aug 2024 (actual). Primary completion is estimated for May 2028, 45 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 2, 2024
First posted
Jul 10, 2024
StartActual
Aug 22, 2024
Primary completionEst.
May 2028
CompletionEst.
May 2028
Last update
Mar 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06494072
Responsible party
Michelle Mitchell (Associate Professor of Pediatric Infectious Diseases, Medical College of Wisconsin) — Principal investigator
First posted
Jul 10, 2024
Start date
Aug 22, 2024
Primary completion
May 2028 (estimated)
Completion
May 2028 (estimated)
Last update
Mar 2, 2026

Study contacts

Michelle Mitchell, MD
Contact
mimitchell@mcw.edu
414-337-7070
Khaled AL zubaidi, MD
Contact
kalzubaidi@mcw.edu
414-337-7070
Michelle Mitchell
principal investigator · Medical College of Wisconsin

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Ampicillin · Ceftriaxone · Amoxicillin · Sulbactam · Clavulanic Acid · Clindamycin · Cefprozil · Levofloxacin

Start the discussion